Publications by authors named "Ewa Borkowska"
Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Postepy Dermatol Alergol
August 2022
Introduction: Infliximab (IFX) is a monoclonal antibody that binds to and neutralizes TNF-α. IFX (Remicade) was approved by the U.S.
View Article and Find Full Text PDFArticle Synopsis
- Biological agents like TNF-α inhibitors (e.g., Adalimumab) and IL-12/IL-23 blockers (e.g., Ustekinumab) are used to treat moderate to severe plaque psoriasis in patients unresponsive to standard treatments.
- * The study involved 620 patients, where Adalimumab did better in achieving significant skin improvement metrics (PASI scores) at weeks 16, 28, and 40 compared to Ustekinumab.
- * Adalimumab not only showed superior clinical efficacy but also significantly improved the quality of life for patients compared to Ustekinumab.
Background: Pulmonary blastoma (PB) comprises a rare heterogeneous group of lung tumours typically containing immature epithelial and mesenchymal structures that imitate the embryonic lung tissue and extremely rarely occurs during pregnancy. Although cough and haemoptysis are the most common PB symptoms, they usually indicate other serious pregnancy-related complications.
Case Presentation: The article presents the unusual case of a 22-year-old pregnant woman diagnosed with PB during pregnancy.
Objective: Apart from having an effect on energy balance, leptin is also involved in cardiovascular regulation and in the pathogenesis of obesity-associated hypertension. We investigated the effect of leptin on nitric oxide (NO) production.
Research Methods And Procedures: Wistar rats were placed in metabolic cages, and urine was collected in 2-hour periods.